Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous magnesium sulfate for ventricular rate control in acute atrial fibrillation
IRCT20260509069313N1Phase 3Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of magnesium sulfate in Atrial fibrillation (AFib) (3 arms), sponsored by Ardabil University of Medical Sciences. Primary endpoints: Heart rate less than 90 bpm at 4 hours after injection and Percentage of heart rate reduction at 4 hours after injection. Started May 2026; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20260509069313N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260509069313N1.